newsfilter
← Latest News
GlobeNewswire·

Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

  • Reviva Pharmaceuticals filed a provisional patent application for a new form of brilaroxazine to extend commercial exclusivity through 2046.
  • The company plans to use the new brilaroxazine form in the RECOVER-2 Phase 3 trial & future NDA submission, with FDA feedback expected in mid-2026.
  • Patient enrollment for the RECOVER-2 registrational Phase 3 trial in schizophrenia is anticipated to begin in Q3 2026.
  • Reviva published vocal biomarker data from the RECOVER Phase 3 trial in the journal Biological Psychiatry.
  • The company completed a public equity offering in March 2026, raising $10.0 million in gross proceeds.
  • Reviva's common stock will transition from Nasdaq to the OTCQB Venture Market on May 14, 2026, retaining the "RVPH" ticker.
  • For the quarter ended March 31, 2026, Reviva reported a net loss of $3.2 million, or $0.46 per share, adjusted for a 1:20 reverse stock split.
  • Cash & cash equivalents totaled $22.2 million as of March 31, 2026, compared to $14.4 million at the end of 2025.
  • Additional publications on brilaroxazine & partnership opportunities are anticipated in 2026.